中國醫療集團(08225.HK):可能延遲刊發2022年年度業績 將自4月3日起停牌
格隆匯3月28日丨中國醫療集團(08225.HK)發佈公吿,由於關於應收賬款的評估,核數師需要和評估師進行進一步的溝通,以及重要確認函未回,集團截至2022年12月31日止年度的財務報表審核準備工作已延誤。因此,核數師需要額外時間審核2022年年度業績,公司預期可能無法於2023年3月31日或之前刊發2022年度的經審核年度業績。倘可能延遲刊發2022年年度業績及寄發2022年年度報吿被落實,公司股份將自2023年4月3日上午九時正起暫停於聯交所買賣,直至公司刊發有關2022年年度業績的公吿及寄發2022年年度報吿為止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.